Advertisement


Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic Breast Cancer: Maintenance Therapy Comparison

ASCO 2026

Advertisement

Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (Abstract 1005).



Related Videos

Gynecologic Cancers

Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease

Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.

Breast Cancer
Gynecologic Cancers

Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer

Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513). 

Immunotherapy

Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden

Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580). 

Lung Cancer

Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105

Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III Alliance A081105 trial, which evaluated adjuvant erlotinib vs observation after complete resection of EGFR-mutant non–small cell lung cancer (NSCLC) (Abstract 8001). 

Breast Cancer

Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer

Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone receptor (HR)-positive, HER2-negative breast cancer, including genomic testing and systemic therapy.

Advertisement

Advertisement




Advertisement